Development and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study

Year 2020, Volume: 50 Issue: 1, 6 - 15, 01.04.2020

Emrah Dural Süleyman Çetin Aslı Bolayır Burhanettin Çiğdem

Abstract

Background and Aims: Carbamazepine (CBZ) is an antiepileptic drug, which is prescribed as a first-line drug for the treatment of partial and generalized tonic–clonic epileptic seizures. The aim of this study was to develop and validate a simple, fast and reliable HPLC method for the determination of carbamazepine in human plasma. Methods: Chlorpromazine (CPR) was used as an internal standard. The separation was conducted with a C18 reverse-phase column (150x3.9 mm, 5 µm) at 30°C, using a mobile phase prepared with 20 mM KH2PO4, acetonitrile and methanol (6:3:1, v/v/v) by isocratic elution. Results: The method was linear between 0.5 and 40 µg/mL, determined by 10 individual calibration points. Total run time was ≤ 5 mins. Accuracy (RE%) values were determined between (-5.6) and 3.6%, and precision was determined at ≤4.2%. Limit of detection (LOD) was 0.04 µg/mL. The robustness test results of the method showed good values. Plasma CBZ of (n=30) those receiving CBZ quantities ranging from 0.2 to 1.2 g/day were measured with this method, and following analyses of their concentrations were found to be between 0.1 and 11.4 µg/mL (6.2±2.4 µg/mL). While all plasma sample analyses were applied properly, it was observed that 16 (53.3%) of the plasma samples had CBZ lower than the recommended range. In addition to that, female patient plasma-CBZ levels were found significantly higher than male plasma contents (p<0.05). Conclusion: This method was found suitable for the analysis of plasma samples collected during the therapeutic drug monitoring (TDM) of patients treated with CBZ.

Keywords

Carbamazepine, plasma, therapeutic drug monitoring, high-performance liquid chromatography, ultraviolet detection

References

• • Auer, M. E., Griesser, U. J., & Sawatzki J. (2003). Qualitative and quantitative study of polymorphic forms in drug formulations by near infrared FT-Raman spectroscopy. Journal of Molecular Structure, 661-662(1–3), 307–317.
• • Bertilsson, L. (1978). Clinical pharmacokinetics of carbamazepine. Clinical Pharmacokinetics, 3(2), 128-143.
• • Brunton, L. L., Knollmann, B. C., & Hilal-Dandan, R. (2018). Goodman & Gilman’s The pharmacological basis of therapeutics. New York, NY: McGraw Hill Medical.
• • Bugamelli F., Sabbioni, C., Mandrioli, R., Kenndler, E., Albani, F., & Raggi, M. A. (2002). Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. Analytica Chimica Acta, 472(1–2), 1–10.
• • Chbili, C., Hassine, A., Laouani, A., Amor, S. B., Nouira, M., Ammou, S. B., & Saguem, S. (2017). The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Archives of Medical Science, 13(2), 353–360.
• • Chen, C. H., & Lin, S. K. (2012). Carbamazepine treatment of bipolar disorder: A retrospective evaluation of naturalistic long-term outcomes. BMC Psychiatry, 12, 47.
• • Cottencin, O., Regnaut, N., Thevenon-Gignac, C., Thomas, P., Goudemand, M., Debruille, C., & Robert, H. (1995). Carbamazepine-fluvoxamine interaction. Consequences for the carbamazepine plasma level. Encephale, 21(2), 141–145.
• • Datar, P. A. (2015). Quantitative bioanalytical and analytical method development of dibenzazepine derivative, carbamazepine: A review. Journal of Pharmaceutical Analysis, 5(4), 213–222.
• • Deeb, S., McKeown, D. A., Torrance, H. J., Wylie, F. M., Logan, B. K, & Scott K. S. (2014). Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases. Journal of Analytical Toxicology, 38(8), 485–494.
• • Domingues, D. S., Pinto, M. A. L., de Souza, I. D., Hallak, J. E., Crippa, J. A., & Queiroz, M. E. (2016). Determination of drugs in plasma samples by high-performance liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients. Journal of Analytical Toxicology, 40(1), 28–36.
• • Dordević, S., Kilibarda, V., & Stojanović, T. (2009). Determination of carbamazepine in serum and saliva samples by high performance liquid chromatography with ultraviolet detection. Vojnosanitetski pregled, 66(5), 347–352.
• • Ezzeldin, E., Shahat, A. A., & Basudan, O. A. (2013). Development and validation of an HPLC method for the determination of carbamazepine in human plasma. Life Science Journal, 10(4), 2159– 2163.
• • Farias, M., & Carneiro, R. (2014). Simultaneous quantification of three polymorphic forms of carbamazepine in the presence of excipients using raman spectroscopy. Molecules, 19(9), 14128– 14138.
• • Ferreira, A., Rodrigues, M., Oliveira, P., Francisco, J., Fortuna, A., Rosado, L., Rosado, P. ... Alves, G. (2014). Liquid chromatographic assay based on microextraction by packed sorbent for therapeutic drug monitoring of carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin and the active metabolites carbamazepine-10,11epoxide and licarbazepine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 971, 20–29.
• • Fortuna, A., Sousa, J., Alves, G., Falcão, A., & Soares-Da-Silva, P. (2010). Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Analytical and Bioanalytical Chemistry, 397(4), 1605–1615.
• • Frag, E. Y. Z., Zayed, M. A., Omar, M. M., Elashery, S. E. A., & Mohamed, G. G. (2012). Spectrophotometric determination of carbamazepine and mosapride citrate in pure and pharmaceutical preparations. Arabian Journal of Chemistry, 5(3), 375–382.
• • Franceschi, L., & Furlanut, M. (2005). A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. Pharmacological Research, 51(4), 297–302.
• • Grunze, H. C., Normann, C., Langosch, J., Schaefer, M., Amann, B., Sterr, A., Schloesser, S ... Walden, J. (2001). Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. Journal of Clinical Psychiatry, 62(6), 464–468.
• • ICH Guideline Q2 (R1) (2005). Validation of Analytical Procedures: Text and Methodology.
• • Juhacik, M. P., & Jenkins, A. J. (2009). Comparison of liquid/liquid and solid phase extraction for alkaline drugs. Journal of Chromatographic Science, 47(7), 553–557.
• • Koristkova, B., Bergman, U., Grundmann, M., Brozmanova, H., & Sjöqvist, F. (2006). Therapeutic monitoring of antiepileptic drugs: A comparison between a Czech and a Swedish University Hospital. Therapeutic Drug Monitoring, 28(5), 594–598.
• • Lajeunesse, A., Vernouillet, G., Eullaffroy, P., Gagnon, C., Juneau, P., & Sauvé, S. (2009). Determination of carbamazepine in aquatic organisms by liquid-liquid extraction and liquid chromatographytandem mass spectrometry. Journal of Environmental Monitoring, 11(4), 723–725.
• • Leite, C. E., Petersen, G. O., Lunardelli, A., & Thiesen, F. V. (2009). A high-performance liquid chromatography method for the determination of carbamazepine and carbamazepine-10,11epoxide and its comparison with chemiluminescent immunoassay. Clinical Chemistry and Laboratory Medicine, 47(4), 458–463.
• • Marino, S. E., Birnbaum, A.K., Leppik, I.E., Conway, J. M., Musib, L. C., Brundage, R. C., Ramsay, R.-E. … Cloyd, J.C. (2012). Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clinical Pharmacology & Therapeutics, 91(3), 483–488.
• • Matar, K. M., Nicholls, P. J., Tekle, A., Bawazir, S. A., & Al-Hassan, M. I. (1999). Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma. Therapeutic Drug Monitoring, 21(5), 559–566.
• • Mimaki, T. (1998). Clinical pharmacology and therapeutic drug monitoring of zonisamide. Therapeutic Drug Monitoring, 20(6), 593–597.
• • Minkova, G., & Getova, D. (2001) Determination of carbamazepine and its metabolite carbamazepine-10,11-epoxide in serum with gas-chromatography mass spectrometry. Methods and Findings in Experimental and Clinical Pharmacology, 23(9), 481–485.
• • Misaka, S., Nakamura, R., Uchida, S., Takeuchi, K., Takahashi, N., Inui, N., Kosuge, K., … Watanabe, H. (2011) Effect of 2 weeks’ consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. Clinical Therapeutics, 33(2), 246–252.
• • Mittal, A., & Das, S. (2012). Carbamazepine-induced hepato-splenomegaly with erythematous rashes in a child. Indian Journal of Pharmacology, 44(2), 268–269.
• • Mowafy, H. A., Alanazi, F. K., El Maghraby, & G. M. (2012). Development and validation of an HPLC–UV method for the quantification of carbamazepine in rabbit plasma. Saudi Pharmaceutical Journal, 20(1), 29–34. • Obermann, M. (2010). Treatment options in trigeminal neuralgia. Therapeutic Advances in Neurological Disorders, 3(2), 107–115.
• • Punyawudho, B., Ramsay, E. R., Brundage, R. C., Macias, F. M., Collins, J. F., & Birnbaum, A. K. (2012). Population pharmacokinetics of carbamazepine in elderly patients. Therapeutic Drug Monitoring, 34(2), 176–181.
• • Queiroz, R. H., Bertucci, C., Malfará, W. R., Dreossi, S. A., Chaves, A. R., Valério, D. A., & Queiroz, M. E. (2008). Quantification of carbamazepine, carbamazepine-10,11-epoxide, phenytoin and phenobarbital in plasma samples by stir bar-sorptive extraction and liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 48(2), 428–434.
• • Rani, S., & Malik, A.K. (2012). A novel microextraction by packed sorbent-gas chromatography procedure for the simultaneous analysis of antiepileptic drugs in human plasma and urine. Journal of Separation Science, 35(21), 2970–2977.
• • Sánchez, A., García, R., Abadín, J. A., & Durán, J. (2010). Determination of free serum carbamazepine by protein precipitation with sulphosalicylic acid. Pharmacy and Pharmacology Communications, 5, 435–438.
• • Sánchez-Alcaraz, A., Quintana, M. B., López, E., Rodríguez, I., & Llopis, P. (2002). Effect of vigabatrin on the pharmacokinetics of carbamazepine. Journal of Clinical Pharmacy and Therapeutics, 27, 427–430.
• • Sproule, B. A., Naranjo, C. A., Brenmer, K. E., & Hassan, P. C. (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics, 33(6), 454–471.
• • Tanaka, E. (1999). Gender-related differences in pharmacokinetics and their clinical significance. Journal of Clinical Pharmacy and Therapeutic, 24(5), 339–346.
• • Tonic-Ribarska, J., Haxhiu, A., Sterjev, Z., Sterjev, Z., Kiteva, G., Suturkova, L., & Trajkovic-Jolevska, S. (2012). Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in saliva. Acta Pharmaceutica, 62(2), 211–220.
• • Vermeij, T. A. C., & Edelbroek, P. M. (2007). Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 857(1), 40–46.
• • Ware, K., Tillery, E., & Linder, L. (2016). General pharmacokinetic/ pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder. Mental Health Clinician, 6(1), 54–61.